{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:06:44Z","timestamp":1784581604487,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hoc.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:38:42Z","timestamp":1781091522000},"page":"591-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial Therapy for Liver Tumors"],"prefix":"10.1016","volume":"40","author":[{"given":"Zuzanna","family":"Kobus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Yarmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hoc.2026.05.007_bib4","unstructured":"Griscom J.T. and Wolf P.S., Liver metastasis, In: StatPearls, 2025, StatPearls Publishing; Treasure Island (FL)."},{"key":"10.1016\/j.hoc.2026.05.007_bib5","first-page":"2","article-title":"Liver metastasis. Analysis of autopsy data","author":"Pickren","year":"1982","journal-title":"Liver metastasis"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13645706.2018.1432489","article-title":"Transvascular therapy of hepatocellular carcinoma (HCC), status and developments","volume":"27","author":"Gnutzmann","year":"2018","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"29","key":"10.1016\/j.hoc.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","article-title":"From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world","volume":"23","author":"Dimitroulis","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hoc.2026.05.007_bib8","author":"Wolf"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"W28","DOI":"10.2214\/AJR.07.2117","article-title":"Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation","volume":"190","author":"Asayama","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.hoc.2026.05.007_bib10","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"issue":"10127","key":"10.1016\/j.hoc.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","article-title":"Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of Yttrium-90 radioembolization: results in therapy-naive patients","volume":"41","author":"Reimer","year":"2018","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0037-1602591","article-title":"Decision making: intra-arterial therapies for Cholangiocarcinoma-TACE and TARE","volume":"34","author":"Currie","year":"2017","journal-title":"Semin Interv Radiol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12094-023-03299-y","article-title":"Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review","volume":"26","author":"Gonzalez-Flores","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12094-019-02182-z","article-title":"Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM","volume":"22","author":"Vera","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib30","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0130","article-title":"Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer","volume":"11","author":"Puleo","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/1754-9485.12163","article-title":"Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature","volume":"58","author":"Bester","year":"2014","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib32","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29454","article-title":"Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review","volume":"222","author":"Deipolyi","year":"2024","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/cco-22-119","article-title":"Image-guided percutaneous locoregional therapies for hepatocellular carcinoma","volume":"12","author":"Chevallier","year":"2023","journal-title":"Chin Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2026.05.007_bib34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.007_bib35","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/480650","article-title":"Transcatheter arterial chemoembolization: history for more than 30 years","volume":"2012","author":"Guan","year":"2012","journal-title":"ISRN Gastroenterol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.critrevonc.2013.07.003","article-title":"Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review","volume":"88","author":"Idee","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.007_bib37","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00270-021-02968-1","article-title":"CIRSE standards of practice on hepatic transarterial chemoembolisation","volume":"44","author":"Lucatelli","year":"2021","journal-title":"Cardiovasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-018-2133-7","article-title":"Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice","volume":"42","author":"Radosa","year":"2019","journal-title":"Cardiovasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib41","first-page":"469","article-title":"Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma","volume":"6","author":"Bhangoo","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","article-title":"Predictive factors for adverse event outcomes after transarterial radioembolization with Yttrium-90 resin microspheres in Europe: results from the prospective observational CIRT study","volume":"46","author":"Maleux","year":"2023","journal-title":"Cardiovasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.14740\/jocmr2902w","article-title":"The main anatomic variations of the hepatic artery and their importance in surgical practice: review of the literature","volume":"9","author":"Noussios","year":"2017","journal-title":"J Clin Med Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0002-9610(71)90476-4","article-title":"Surgical significance of anatomic variations of the hepatic artery","volume":"122","author":"Suzuki","year":"1971","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1245\/s10434-009-0757-1","article-title":"Vascular anomalies encountered during pancreatoduodenectomy: do they influence outcomes?","volume":"17","author":"Shukla","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2026.05.007_bib46","series-title":"Blood supply and anatomy of the upper abdominal organs: with a descriptive atlas","author":"Michels","year":"1955"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/jcm14020314","article-title":"All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement","volume":"14","author":"Lanza","year":"2025","journal-title":"J Clin Med"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.007_bib48","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.3390\/cancers13205122","article-title":"European multicenter study on degradable starch microsphere TACE: the digestible way to conquer HCC in patients with high tumor burden","volume":"13","author":"Ludwig","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.hoc.2026.05.007_bib49","article-title":"Recent advances in embolic agents for transarterial chemoembolization of hepatocellular carcinoma","volume":"15","author":"Liu","year":"2025","journal-title":"Adv Healthc Mater"},{"issue":"43","key":"10.1016\/j.hoc.2026.05.007_bib50","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib51","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00270-012-0352-x","article-title":"Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma","volume":"35","author":"Sahara","year":"2012","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib52","first-page":"92","article-title":"Transarterial chemoembolization with irinotecan-loaded beads followed by arterial infusion of 5-Fluorouracil for metastatic liver tumors refractory to standard systemic chemotherapy","volume":"8","author":"Irizato","year":"2023","journal-title":"Interv Radiol (Higashimatsuyama)"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"Kulik","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13550-018-0402-8","article-title":"The value of (99m)Tc-MAA SPECT\/CT for lung shunt estimation in (90)Y radioembolization: a phantom and patient study","volume":"8","author":"Allred","year":"2018","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diii.2022.12.002","article-title":"Lung shunt fraction calculations before Y-90 transarterial radioembolization: Comparison of accuracy and clinical significance of planar scintigraphy and SPECT\/CT","volume":"104","author":"Young","year":"2023","journal-title":"Diagn Interventional Imaging"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0041-1735569","article-title":"Post Yttrium-90 imaging","volume":"38","author":"Rice","year":"2021","journal-title":"Semin Interv Radiol"},{"issue":"9319","key":"10.1016\/j.hoc.2026.05.007_bib57","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib58","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ejso.2022.01.009","article-title":"The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis","volume":"48","author":"Lv","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.007_bib61","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","article-title":"Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study","volume":"30","author":"White","year":"2019","journal-title":"J Vasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","article-title":"Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study","volume":"36","author":"Rafi","year":"2013","journal-title":"Cardiovasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.09091076","article-title":"Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization","volume":"255","author":"Kim","year":"2010","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000530700","article-title":"Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management","volume":"13","author":"Ye","year":"2024","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.007_bib65","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00270-017-1648-7","article-title":"Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma","volume":"40","author":"Chan","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jvir.2019.09.028","article-title":"Outcomes of Yttrium-90 radioembolization for unresectable combined biphenotypic hepatocellular-cholangiocarcinoma","volume":"31","author":"Malone","year":"2020","journal-title":"J Vasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061371","article-title":"Review of intra-arterial therapies for colorectal cancer liver metastasis","volume":"13","author":"Kwan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.007_bib68","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.hoc.2026.05.007_bib69","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib70","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13063-018-2782-5","article-title":"Randomized embolization trial for NeuroEndocrine tumor metastases to the liver (RETNET): study protocol for a randomized controlled trial","volume":"19","author":"Chen","year":"2018","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.007_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7131","article-title":"Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: study protocol for a prospective, randomized, controlled trial","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.007_bib72","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/j.ejrad.2013.08.046","article-title":"Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer","volume":"82","author":"Eichler","year":"2013","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.007_bib73","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2013.85","article-title":"A randomised phase II\/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma","volume":"108","author":"Meyer","year":"2013","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.007_bib74","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1007\/s13277-014-2340-z","article-title":"Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review","volume":"35","author":"Xie","year":"2014","journal-title":"Tumour Biol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.007_bib75","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jvir.2025.06.014","article-title":"Comparison of the effectiveness of transarterial bland embolization and transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a propensity score matched study of 980 patients","volume":"36","author":"Zhang","year":"2025","journal-title":"J Vasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.007_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2026.05.007_bib78","article-title":"DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study","volume":"10","author":"Wang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.007_bib79","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0002-9610(91)91111-U","article-title":"Role of radiation after operative palliation in cancer of the proximal bile ducts","volume":"161","author":"Grove","year":"1991","journal-title":"Am J Surg"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.007_bib81","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial chemoembolization and radioembolization for unresectable intrahepatic Cholangiocarcinoma-a systemic review and meta-analysis","volume":"44","author":"Mosconi","year":"2021","journal-title":"Cardiovasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.007_bib82","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000539301","article-title":"A changing role of transarterial chemoembolization in the era of immune checkpoint inhibitor plus Anti-VEGF\/TKI plus transarterial chemoembolization: from total embolization to partial embolization (Immune boost transarterial chemoembolization)","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"issue":"10474","key":"10.1016\/j.hoc.2026.05.007_bib83","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.hoc.2026.05.007_bib84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.007_bib85","doi-asserted-by":"crossref","first-page":"683","DOI":"10.21873\/invivo.11824","article-title":"Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study","volume":"34","author":"Fiorentini","year":"2020","journal-title":"In Vivo"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882600047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882600047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:31:14Z","timestamp":1784579474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882600047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S088985882600047X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial Therapy for Liver Tumors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}